Dror Ortho-Design, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Dror Ortho-Design, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $2.6K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.0K | Mar 23, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.54M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($5.78M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($3.57M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | ($1.68M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($170.5K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($168.0K) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($134.2K) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($115.9K) | May 7, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.22M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($5.22M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($4.38M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | ($1.69M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($170.3K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($167.7K) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($133.9K) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($115.7K) | May 7, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $815.9K | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.54M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.06M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $850.7K | Apr 1, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.06M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($2.74M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($2.39M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | ($1.52M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($136.1K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($109.7K) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($76.8K) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($66.5K) | May 7, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $966 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $25.8K | Feb 27, 2026 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $258.9K | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $662.7K | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $3.46M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $1.14M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $192.4K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $328.1K | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $433.8K | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $512.7K | May 7, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.13M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.03M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $302.3K | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $547.3K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $737.5K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $702.7K | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $640.4K | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $585.1K | May 7, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.87M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($368.0K) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $3.16M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $596.1K | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $2.26M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | ($374.6K) | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($206.6K) | Mar 23, 2022 |
| FY2020 | Dec 31, 2018 | ($72.4K) | Mar 24, 2021 |
| FY2019 | Dec 31, 2017 | $43.5K | May 7, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.05M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($19.51M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($13.73M) | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | ($10.16M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($41.62M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($41.45M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($41.29M) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($41.15M) | May 7, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $3.35M | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $1.04M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $185.9K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $322.0K | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $431.7K | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $508.5K | May 7, 2020 |
| FY2019 | Dec 31, 2017 | $575.1K | May 7, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 23, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 23, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 957.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 957.00M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 495.45M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | 437.74M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 202.31M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 202.31M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | 202.31M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | 202.31M | May 7, 2020 |